Adenovirus-mediated IKK beta KA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis

SANLIOGLU A. D., KOKSAL I., KARACAY B., Baykara M., LULECI G., Sanlioglu S.

CANCER GENE THERAPY, cilt.13, sa.1, ss.21-31, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 1
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1038/sj.cgt.7700877
  • Dergi Adı: CANCER GENE THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.21-31
  • Anahtar Kelimeler: prostate carcinoma, TRAIL resistance, decoy receptors, IKK, NF-KAPPA-B, LIGAND (TRAIL)-INDUCED APOPTOSIS, FADD-DEPENDENT APOPTOSIS, LUNG-CANCER CELLS, DECOY RECEPTOR, IN-VIVO, TNF-ALPHA, CONSTITUTIVE ACTIVATION, CHEMOTHERAPEUTIC DRUGS, DEATH RECEPTORS
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Despite the fact that tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) can selectively induce apoptosis in cancer cells, TRAIL resistance in cancer cells has challenged the use of TRAIL as a therapeutic agent. First, prostate carcinoma cell lines (DU145, LNCaP and PC3) were screened for sensitivity to adenovirus delivery of TRAIL (Ad5hTRAIL). As amplified Ikappa B kinase (IKK) activity is responsible for the constitutive nuclear factor-kappa B (NF-kappa B) activation leading to uncontrolled cell growth and metastasis, a dual vector approach using both an adenovirus vector ( Ad) expressing the dominant-negative mutant of IKK beta (AdIKK beta KA) and Ad5hTRAIL was employed to determine if prostate cancer cells were sensitized to TRAIL in the setting of IKK inhibition. Inhibition of the NF kappa B pathway through IKK blockade sensitized all three prostate cancer cell lines to TRAIL, regardless of NF-kappa B activation or decoy receptor gene expression. Moreover, a novel quantitative real-time RT-PCR assay and conventional flow cytometry analysis indicated that TRAIL-resistant DU145 and LNCaP cells, but not TRAIL-sensitive PC3 cells, expressed substantial amounts of TRAIL Decoy Receptor 4. In conclusion, TRAIL decoy receptor expression appeared to be the chief determinant of TRAIL resistance encountered in prostate carcinoma cell lines.